November is C. difficile awareness month — an opportunity to revisit one of the most consequential infections in modern medicine and to highlight the microbiome-restoring therapies emerging to treat it.
What CDI does
Clostridioides difficile is a Gram-positive, spore-forming bacterium that causes severe diarrhea and life-threatening colitis. In the United States alone, more than 200,000 infections occur annually, more than 12,000 people die, and the system absorbs roughly $1B in attributable healthcare costs.
Most cases of CDI are secondary to antibiotic therapy, especially in elderly and hospitalized patients. Antibiotics destroy the protective communities of bacteria in the gut, allowing C. difficile spores to germinate and overgrow — part of the broader pattern driving post-pandemic antimicrobial resistance.
Diagnostic challenges
Detecting CDI is harder than it sounds. Toxin enzyme immunoassays (EIAs) and nucleic acid amplification tests (NAATs) are the most common tools, but they don't always distinguish active infection from asymptomatic colonization. Misclassification leads to unnecessary antibiotic exposure — exactly what put the patient at risk in the first place.
Why standard treatment falls short
Metronidazole and vancomycin remain the standard of care, with fidaxomicin and the monoclonal antibody bezlotoxumab providing incremental gains. But every antibiotic round further depletes the gut microbiome, and recurrence rates run 20–30% — a treadmill that's hard to step off.
Microbiome-restoring therapies
The most promising new approaches restore the microbiome instead of further depleting it. Fecal microbiota transplantation (FMT) has shown striking efficacy in recurrent CDI by transferring a diverse microbial community from a screened donor. Standardized live biotherapeutic products — essentially defined microbial consortia delivered as drugs — are now reaching late-stage clinical development. Vaccine candidates targeting C. difficile toxins are also progressing.
Prevention is still the best medicine
Hand hygiene with soap and water (alcohol does not kill spores), environmental cleaning, and disciplined antibiotic stewardship remain the most cost-effective ways to reduce CDI. Better diagnostics — including metagenomic profiling of the gut microbiome — will help identify high-risk patients earlier and target interventions where they matter most, an approach that connects to broader work on the gut microbiome's role in human health.
Frequently asked questions
What is C. difficile infection?
CDI is a gut infection caused by the spore-forming bacterium Clostridioides difficile. It produces toxins that inflame the colon and cause severe diarrhea. Most cases occur after antibiotic therapy disrupts the protective gut microbiome.
Why does CDI recur so often?
Standard treatments like vancomycin and metronidazole kill C. difficile but further deplete the surrounding microbiome that would normally keep it in check. Without a diverse microbial community, recurrence rates run 20–30%.
What is fecal microbiota transplantation?
FMT transfers stool from a screened healthy donor into the gut of a patient with recurrent CDI. By restoring a diverse microbiome, FMT has shown high cure rates for recurrent disease and inspired a new class of standardized live biotherapeutic products.